Mira Pharmaceuticals Q2 2026 net loss narrows to $1.21 million; revenue remains no revenue

Reuters2026/08/12 20:27

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mira Pharmaceuticals posted a net loss of USD 1.21 million for the quarter ended June 30, 2026, narrowing from USD 1.54 million.
Loss per share improved to USD 0.03 from USD 0.09, with no revenue reported in either period.
Operating expenses fell to USD 1.16 million from USD 1.55 million, as general and administrative costs dropped to USD 450,330.
Research and development spending rose to USD 705,789 from USD 496,197, while interest income increased to USD 35,130 from USD 8,623.
Ketamir-2 completed Phase 1 dosing; Phase 2a CIPN trial targeted for Q1 2027, while MIRA-55 and SKNY-1 advanced toward IND-enabling work.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037366), on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mira Pharmaceuticals Q2 2026 net loss narrows to $1.21 million; revenue remains no revenue

You may also like

Crypto prices